

October 22, 2021 | Issue 31

Resilience Report

Brief insights and the latest innovations in emergency management and health security.

The U.S. breathes a sigh of relief as COVID-19 cases continue to decline, but the virus continues to headline recent news. During this week's Resilience Report, we provide a rundown of COVID-19 vaccinations and their current status. We also share some recent climate change and supply chain developments and look forward to Halloween.



Non-COVID Vaccination News.

With the focus on the COVID-19 vaccine, you might have missed the announcement of another vaccine that is being hailed as a <u>historic breakthrough</u> in the fight against malaria. The groundbreaking vaccine was <u>approved</u> on October 6 but is just part of a comprehensive prevention strategy against the disease, which killed over 400,000 people in 2019.

Climate Change and Emergency Management.

Climate change remains in the news. <u>NASA</u> announced that it would begin using its unique perspective from space to examine the effects of climate change on earth. And earlier this week, FEMA administrator, Deanne Criswell, discussed the <u>important role of emergency</u> <u>managers</u> in the fight against climate change. This point was underscored recently, as the <u>Santa Ana winds</u> continue to impact the wildfire season in southern California.

Supply Chain Woes.

The supply chain, normally not something that most Americans pay close attention to, has been in the forefront of the news lately and it looks like the issues <u>aren't going to end</u> anytime soon. There are concerns that it is affecting economic growth <u>across the world</u>, not just within the U.S. And even worse, there are increasing concerns about how it will <u>affect the holidays</u>.

The Rest of Cybersecurity Awareness Month.

As Cybersecurity Awareness Month winds down, officials are continuing to focus on critical elements, including the need for <u>collaboration among federal</u>, <u>state</u>, <u>and local agencies</u>, both

during incidents and in sharing information in general.



Every week, we'll dedicate space for a hot topic that we think is especially important for emergency managers to read. While we could talk about COVID-19 developments each issue, we took a break over our last few Resilience Reports to touch on other important topics. This week, however, we provide an update on the most recent COVID-19 news.

- As Merck's oral antiviral drug <u>Molnupiravir</u> awaits Emergency Use Authorization (EUA), concerns are mounting about its impact on <u>vaccination rates</u> and ongoing <u>equity</u> issues. The <u>Gates Foundation</u> has committed to donating \$120M to the generic manufacturers of Molnupiravir, but critics say this is not enough.
- Some of the most publicized efforts to increase vaccination rates such as statewide lotteries, have been found to be <u>ineffective</u>. As officials refine their outreach approach, marketing professionals recommend <u>market segmentation</u> strategies to better understand public behavior.
- COVID-19 has aggravated the threats, violence, and harassment that <u>Public</u> <u>Health</u>, <u>Medical</u>, and <u>Scientific</u> professionals face. While employers struggle to accommodate the security and safety requirements of its employees, some Public Health officials are calling for <u>federal protection</u>. The full letter from <u>NACCHO</u> is here.

The Latest COVID-19 News and Your Status

As the COVID-19 vaccine continues to headline with the upcoming approval of the Pfizer vaccine for <u>children ages 5-11</u> and booster shots for adults, it can be difficult to keep track of it all. In the table below, we summarize the latest news and research.

Vaccine Characteristic	Pfizer-BioNTech	Moderna	Johnson & Johnson
Current Status	 FDA-approved for age 16+ EUA for ages 12-15 Awaiting EUA for ages 5-11 	 EUA for age 18+ EUA delayed for ages 12-17 given concerns of myocarditis side effect 	• EUA for age 18+
Boosters	 Age 65+ LTCF residents Ages 18-64 with underlying conditions Ages 18-64 with work/living conditions that heightens exposure 	 Age 65+ LTCF residents Ages 18-64 with underlying conditions Ages 18-64 with work/living conditions that heightens exposure 	 Booster shot for age 18+
Efficacy Studies	 04/2021: 91.3% effective up to 6 months following 2nd dose¹ 10/2021: 88% effective after 1st month post vaccination to 47% at 5-6 months² 09/2021: Protection declined 4 months post vaccination³ 	 04/2021: 90% effective 6 months median follow-up post 2nd dose⁴ 09/2021: 93% effective against hospitalization for U.S. adults without immunocompromising conditions³ 09/2021: Among healthcare workers, vaccine effectiveness was at its peak (96.3%) during weeks 3/4 after second dose⁵ 	 02/2021: 72% effective against moderate to severe cases across U.S.⁶ 09/2021: Protection increases 12-fold when a booster shot is administered at six months⁷

Sources: ¹ <u>Pfizer Press Release</u> ² <u>Kaiser Permanente Study</u> ³ <u>CDC Report</u> ⁴ <u>Moderna Press</u> <u>Release</u> ⁵ <u>New England Journal of Medicine</u> ⁶ <u>Johnson & Johnson EUA</u> <u>Presentation</u> ⁷ <u>Johnson & Johnson Press Release</u>

Need help with planning for COVID-19 vaccine boosters? Shoot our resident public health experts an <u>email</u> to learn more!



Need a Costume?

Here's a round up of the <u>most popular costumes</u> (including Squid Game, Ted Lasso, and LeBron from Space Jam), the <u>most popular candy</u>, and the best <u>Halloween recipes</u> to end October with a BOOm.

Get Your Spooky On.

From haunted hay rides to a live performance of *The Nightmare Before Christmas* and Universal Studios' annual Halloween Horror Nights festival, LA has a <u>spooky activity</u> for every ghoul and ghost.

A Day to Load Up on Carbs!

Monday is World Pasta Day. To elevate your pasta game, we have <u>35 pasta recipes</u> and <u>20</u> <u>fun facts</u> about the beloved noodle (the world consumes 13 million tons of pasta each year!).



We're Here to Support You

If you need help with vaccine ops, COVID-19 AARs, or anything in between, shoot us an email at <u>donna@constantassociates.com</u>. We are here to help.

CONSTANT is certified as an 8(a) and Economically Disadvantaged Woman Owned Business (EDWOSB) and as a Great Place To Work. We are an Equal Opportunity Employer.

Got this as a forward? You can subscribe to receive future issues of Resilience Report by clicking <u>here</u>.

Great Place To Work。 Certified AUG 2021-AUG 2022 USA

Resilience is CONSTANT.™

